Height SDS during the first 2 years of GH treatment and at final height.

<p>Error bars are medians with interquartile ranges. Significant statistical differences between height SDS at baseline and others time points: *** P < 0.0001 (2-way repeated-measures ANOVA plus Bonferroni post-test).</p

Evolution of the hormonal impairment according to the initial presentation.

<p>(A) Frequency of GH, ACTH and/or TSH deficiencies in neonates (n = 10) and patients with growth retardation, at baseline (n = 47) and at final height (n = 21). Significant statistical difference in the number of cases of combined pituitary hormone deficiency between groups of neonates and patients with growth retardation: ** P < 0.001 (chi square test). The gonadotropic axis was evaluated in neonates (during “mini-puberty”) and in patients of postpubertal age. LH/FSH deficiency was found in 9 of 10 neonates (90%) and 12 of 21 patients with growth retardation at final height (57%); this was not statistically different (P = 0.1522). (B) Evolution of ACTH, and TSH deficiencies throughout childhood in patients with growth retardation who reached their final height (n = 21). All patients had GHD at diagnosis.</p

Characteristics of patients with extra-pituitary malformations (syndromic group).

<p>SOD: septo-optic dysplasia, ASD: atrial septal defect, VSD: ventricular septal defect</p><p>Characteristics of patients with extra-pituitary malformations (syndromic group).</p

Clinical and radiological characteristics at baseline of the 67 patients with PSIS and the subgroups.

<p>Values are medians (range) or percentages as indicated. P values were calculated using the Mann-Whitney test</p><p>Clinical and radiological characteristics at baseline of the 67 patients with PSIS and the subgroups.</p